Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28.

CAS  PubMed  PubMed Central  Google Scholar 

Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BNM. Molecular imaging approaches in dementia. Radiology. 2021;298:517–30.

PubMed  Google Scholar 

Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol [Internet]. 2022;21:726–34. Available from: https://doi.org/10.1016/S1474-4422(22)00168-5

Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti DE, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2024;20:221–33.

CAS  PubMed  Google Scholar 

Smith R, Cullen NC, PichetBinette A, Leuzy A, Blennow K, Zetterberg H, et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 2023;19:2497–507.

CAS  PubMed  Google Scholar 

Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer Disease: A head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961–71.

PubMed  PubMed Central  Google Scholar 

Van Rossum IA, Visser PJ, Knol DL, Van Der Flier WM, Teunissen CE, Barkhof F, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in alzheimer’s disease. J Alzheimers Dis. 2012;29:319–27.

PubMed  Google Scholar 

Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement. 2024;20:5143–69.

PubMed  PubMed Central  Google Scholar 

Bollack A, Pemberton HG, Collij LE, Markiewicz P, Cash DM, Farrar G, et al. Longitudinal amyloid and tau PET imaging in Alzheimer’s disease: A systematic review of methodologies and factors affecting quantification. Alzheimers Dement. 2023;19:5232–52.

PubMed  Google Scholar 

Burnham SC, Iaccarino L, Pontecorvo MJ, Fleisher AS, Lu M, Collins EC, et al. A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles. Brain Commun [Internet]. 2024;6:1–25. Available from: https://doi.org/10.1093/braincomms/fcad305

Zhang H, Wang M, Lu J, Bao W, Li L, Jiang J, et al. Parametric estimation of reference signal intensity for semi-quantification of tau deposition: A flortaucipir and [18F]-APN-1607 Study. Front Neurosci. 2021;15.

Bischof GN, Endepols H, van Eimeren T, Drzezga A. Tau-imaging in neurodegeneration. Methods. 2017;130:114–23.

CAS  PubMed  Google Scholar 

Tahmi M, Bou-Zeid W, Razlighi QR. A fully automatic technique for precise localization and quantification of amyloid-b PET scans. J Nucl Med. 2019;60:1771–9.

CAS  PubMed  PubMed Central  Google Scholar 

Kolinger GD, García DV, Willemsen ATM, Reesink FE, de Jong BM, Dierckx RAJO, et al. Amyloid burden quantification depends on PET and MR image processing methodology. PLoS ONE. 2021;16:1–19.

Google Scholar 

Carlson ML, Smith V, Johns E, Young CB, Vosslera H, Ward T, et al. MRI- free processing of tau PET images for early detection. Imaging Neurosci [Internet]. 2024;2. Available from: https://doi.org/10.1162/imag_a_00369

Jagust WJ, Koeppe RA, Rabinovici GD, Villemagne VL, Harrison TM, Landau SM. The ADNI PET Core at 20. Alzheimers Dement. 2024;7340–9.

Landau SM, Harrison TM, Baker SL, Boswell MS, Lee JQ, Taggett J, et al. Positron emission tomography harmonization in the Alzheimer’s Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification. Alzheimers Dement. 2024;1–16.

Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, et al. Tau pathology distribution in Alzheimer’s disease corresponds differentially to cognition-relevant functional brain networks. Front Neurosci. 2017;11.

Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur ÖA, et al. Networks of tau distribution in Alzheimer’s disease. Brain. 2018;141:568–81.

PubMed  Google Scholar 

Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015;84:1121–7.

PubMed  PubMed Central  Google Scholar 

Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.

PubMed  Google Scholar 

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA - J Am Med Assoc. 2018;320:1151–62.

CAS  Google Scholar 

Mishra S, Gordon BA, Ph D, Su Y, Ph D, Christensen J, et al. AV-1451 PET Imaging of Tau Pathology in Preclinical Alzheimer Disease: 2017;171–8.

Diedenhofen B, Musch J. Cocor: A comprehensive solution for the statistical comparison of correlations. PLoS ONE. 2015;10:1–12.

Google Scholar 

Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63:20S-26S.

CAS  PubMed  Google Scholar 

Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829–39.

PubMed  PubMed Central  Google Scholar 

Lee CM, Jacobs HIL, Marquié M, Becker JA, Andrea NV, Jin DS, et al. 18F-Flortaucipir binding in choroid plexus: related to race and hippocampus signal. J Alzheimer Dis. 2018;62:1691–702.

CAS  Google Scholar 

Pawlik D, Leuzy A, Strandberg O, Smith R. Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET. Neuroimage [Internet]. 2020;221:117193. Available from: https://doi.org/10.1016/j.neuroimage.2020.117193

Ikonomovic MD, Abrahamson EE, Price JC, Mathis CA, Klunk WE. [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than “off-target” binding. Ann Neurol. 2016;80:307–8.

PubMed  PubMed Central  Google Scholar 

Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain [Internet]. 2023;146:1592–601. Available from: https://doi.org/10.1093/brain/awac333

Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol [Internet]. 2024;271:2053–66. Available from: https://doi.org/10.1007/s00415-023-12148-5

Warmenhoven N, Salvadó G, Janelidze S, Mattsson-Carlgren N, Bali D, Dolado AO, et al. A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests. medRxiv [Internet]. 2024;93:85–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/39006421%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC11245081